Please use this identifier to cite or link to this item:
|Title:||Polypharmacy in elderly patients with cancer: Clinical implications and management|
|Source:||Lees, J., Chan, A. (2011-12). Polypharmacy in elderly patients with cancer: Clinical implications and management. The Lancet Oncology 12 (13) : 1249-1257. ScholarBank@NUS Repository. https://doi.org/10.1016/S1470-2045(11)70040-7|
|Abstract:||More and more elderly people with cancer are treated in oncology clinics worldwide every year, many of whom have comorbid disorders treated with one or more drugs. Moreover, these patients might also take self-prescribed over-the-counter drugs or complementary and alternative medicines, which they might not tell their doctor about. Initiation of chemotherapy with one or more cytotoxic or targeted agents and drugs for treatment of cancer symptoms or toxic effects related to treatment can result in polypharmacy. We examine the clinical implications of polypharmacy. Challenges for the medical teams who treat elderly patients with cancer include identification of what drugs are actually being taken by the patient, avoidance or management of any adverse effects or drug interactions, and reassessing the patient's overall treatment. We address these issues and propose practical recommendations for management of treatment for elderly patients with cancer. © 2011 Elsevier Ltd.|
|Source Title:||The Lancet Oncology|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 15, 2018
WEB OF SCIENCETM
checked on Feb 5, 2018
checked on Feb 19, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.